Chlamydia pneumoniae and the lung

被引:72
作者
Hammerschlag, MR [1 ]
机构
[1] SUNY Hlth Sci Ctr, Dept Paediat, Div Infect Dis, Brooklyn, NY 11203 USA
关键词
asthma; Chlamydia; pneumoniae; community-acquired; pneumonia; pulmonary infection;
D O I
10.1183/09031936.00.16510010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Chlamydia pneumoniae is a frequently occurring respiratory pathogen affecting all age groups. It may cause 5-20% of community-acquired pneumonias in adults and children. The organism has also been implicated as an infectious trigger for asthma. Furthermore, new studies suggest that it may play a role in the pathogenesis of several chronic diseases including atherosclerosis. However, despite the growing significance of C. pneumoniae as a pathogen, progress is hampered by the lack of standardized diagnostic methods including serology and polymerase chain reaction. This makes it practically impossible for the practitioner to make a specific microbiological diagnosis. The lack of standardized methods has also had an adverse effect on treatment trials. The dependence on serology for diagnosis in treatment studies has generated some questionable results. Unless cultures are performed, microbiological efficacy cannot be assessed and it may never be possible to survey for or document the emergence of resistance.
引用
收藏
页码:1001 / 1007
页数:7
相关论文
共 56 条
[41]   ROLE OF CHLAMYDIA-PNEUMONIAE IN ACUTE CHEST SYNDROME OF SICKLE-CELL DISEASE [J].
MILLER, ST ;
HAMMERSCHLAG, MR ;
CHIRGWIN, K ;
RAO, SP ;
ROBLIN, P ;
GELLING, M ;
STILERMAN, T ;
SCHACHTER, J ;
CASSELL, G .
JOURNAL OF PEDIATRICS, 1991, 118 (01) :30-33
[42]   Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD [J].
Miyashita, N ;
Niki, Y ;
Nakajima, M ;
Kawane, H ;
Matsushima, T .
CHEST, 1998, 114 (04) :969-971
[43]   Implications for macrolide treatment in community-acquired pneumonia [J].
Mundy, LM ;
Oldach, D ;
Auwaerter, PG ;
Gaydos, CA ;
Moore, RD ;
Bartlett, JG ;
Quinn, TC .
CHEST, 1998, 113 (05) :1201-1206
[44]  
NORRBY SR, 1997, J ANTIMICROB CHEMOTH, V39, P499
[45]  
PEELING RW, P 9 INT S HUM CHLAM
[46]   Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization [J].
Plouffe, JF ;
Herbert, MT ;
File, TM ;
Baird, I ;
Parsons, JN ;
Kahn, JB ;
RiellyGauvin, KT ;
Best, M ;
Dalieh, S ;
Fass, RJ ;
Francis, S ;
Gray, G ;
Hackman, BA ;
Koletar, SL ;
Maher, WE ;
Mazur, C ;
Minor, J ;
Oglevee, BA ;
Para, MF ;
PorterfieldBaxa, J ;
Rogers, T ;
Saltrom, SJ ;
Sarokis, M ;
ScottTibbs, G ;
Signs, D ;
Stuart, D ;
Tan, J ;
Tumbleson, CS ;
Walker, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1175-1179
[47]   Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39 [J].
Read, TD ;
Brunham, RC ;
Shen, C ;
Gill, SR ;
Heidelberg, JF ;
White, O ;
Hickey, EK ;
Peterson, J ;
Utterback, T ;
Berry, K ;
Bass, S ;
Linher, K ;
Weidman, J ;
Khouri, H ;
Craven, B ;
Bowman, C ;
Dodson, R ;
Gwinn, M ;
Nelson, W ;
DeBoy, R ;
Kolonay, J ;
McClarty, G ;
Salzberg, SL ;
Eisen, J ;
Fraser, CM .
NUCLEIC ACIDS RESEARCH, 2000, 28 (06) :1397-1406
[48]   Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia [J].
Roblin, PM ;
Hammerschlag, MR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :194-196
[49]   USE OF HEP-2 CELLS FOR IMPROVED ISOLATION AND PASSAGE OF CHLAMYDIA-PNEUMONIAE [J].
ROBLIN, PM ;
DUMORNAY, W ;
HAMMERSCHLAG, MR .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (08) :1968-1971
[50]   SUSCEPTIBILITIES TO CLARITHROMYCIN AND ERYTHROMYCIN OF ISOLATES OF CHLAMYDIA-PNEUMONIAE FROM CHILDREN WITH PNEUMONIA [J].
ROBLIN, PM ;
MONTALBAN, G ;
HAMMERSCHLAG, MR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1588-1589